Boehringer Ingelheim Pharmaceuticals, Inc.

Other

James J Crute

Bruno Simoneau

Karl D Hargrave

Anne-Marie Faucher

Bounkham Thavonekham

Christine A Grygon

Steven S Pullen

Marilyn R Kehry

This invention relates to methods for inhibiting herpes replication and for treating herpes infection in a mammal by inhibiting the herpes helicase-primase enzyme complex. This invention also relates to thiazolyphenyl derivatives that inhibit the herpes helicase-primase and to pharmaceutical compositions comprising the thiazolylphenyl derivatives, to methods of using and methods of producing the thiazolylphenyl derivatives.

Anti-herpesvirus compounds and methods for identifying, making and using same

Disclosed is a high throughput compatible assay that is useful for the identification of specific antagonists of TRAF-receptor interactions. The modular flexibility of the assay makes it possible to introduce simple modifications in order to measure the interaction of any TNF receptor cytoplasmic domain (or TRAF-binding protein) with any of the six TRAF proteins, TRAF1, TRAF2, TRAF3, TRAF4, TRAF5 and TRAF6.

High throughput compatible assay for receptor-TRAF interactions

Anti-herpesvirus compounds and methods for identifying, making and using

This invention relates to a solid phase helicase assay for identifying helicase inhibitors. The assay having a model helicase substrate adsorbed on a solid support, the model helicase substrate being an immobilized extended single-stranded nucleic acid polymer hybridized to a labeled helicase reaction product. The presence of the labeled helicase reaction product is detectable in solution on helicase activity. Also described is a method for measuring the helicase inhibiting ability of test substances thus, making the assay useful for identifying pharmaceutically important helicase inhibitors.

Quantitative solid phase helicase assay

Growing community of inventors

Danbury, CT, United States of America

James J Crute